drugset / Trial / NCT07148739
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Phase 4
Recruiting
100 enrolled
Arkansas Children's Hospital Research Institute
National Heart, Lung, and Blood Institute (NHLBI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).
Timeline
- Start
- 2025-06-10
- Primary completion
- 2030-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ivacaftor | Other / unclassified | — | — |
| Subject | elexacaftor | Small molecule | — | — |
| Subject | tezacaftor | Other / unclassified | — | — |